

1 **Title page**

2 **Investigation on the interaction between nifedipine and ritonavir containing**
3 **antivirus regimens: a physiologically-based pharmacokinetic/pharmacodynamic**
4 **analysis**

5
6 **Author names:** Wan-jie Niu^{1,2}, Si-ze Li³, Sha-sha Jin³, Xi-ying Lin³, Meng-wan
7 Zhang¹, Wei-min Cai³, Ming-kang Zhong², Xiao-qiang Xiang^{3*}, Zheng Jiao^{1*}

8 **Author affiliations:**

9 ¹ Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
10 No. 241 West Huaihai Road, Shanghai, 200030, China.

11 ² Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040,
12 China

13 ³ Department of Clinical Pharmacy and Drug Administration, School of Pharmacy,
14 Fudan University, Shanghai, 201203, China.

15

16 ***Corresponding authors**

17 Xiao-qiang Xiang, Department of Clinical Pharmacy and Drug Administration, School
18 of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China

19 E-mail: xiangxq@fudan.edu.cn

20 ORCID: 0000-0002-8683-2603

21

22 Zheng Jiao, PhD, Professor of Clinical Pharmacy,

23 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241
24 West Huaihai Road, Shanghai, 200030, China.

25 E-mail: jiaozhen@online.sh.cn

26 ORCID: 0000-0001-7999-7162

27

28 **Conflict of interest**

29 The authors declare that they have no conflict of interest in their authorship or
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 publication of this paper.

31

32 **Funding**

33 This work was supported by the “2020 Annual Project on Drug Management and
34 Rational Use on Coronavirus Disease 2019 (COVID-19) of Shanghai Jiao Tong
35 University School of Medicine”.

36

37 **Author contribution**

38 **Zheng Jiao:** Conceptualization, Writing-Original draft; Writing-Review & Editing;
39 Supervision; Project administration; Funding acquisition. **Xiao-qiang Xiang:**
40 Methodology; Validation; Resources; Writing-Original draft; Writing-Review &
41 Editing; Supervision; Project administration; Funding acquisition. **Si-ze Li:** Formal
42 analysis; Software; Investigation; Data Curation. **Xi-ying Lin:** Investigation, Formal
43 analysis. **Sha-sha Jin:** Investigation; Visualization. **Meng-wan Zhang:** Data Curation,
44 Funding acquisition. **Ming-kang Zhong** and **Wei-min Cai:** Supervision. **Wan-jie Niu:**
45 Investigation; Writing-Original draft; Writing-Review & Editing; Visualization.

46 **Abstract**

47 **Background and Objective**

48 Hypertension is a common comorbidity of patients with COVID-19, SARS or HIV
49 infection. Those patients are often treated with commonly used antiviral and
50 antihypertensive agents concomitantly, such as ritonavir-containing regimens and
51 nifedipine. Since ritonavir is a strong inhibitor of CYP3A, when nifedipine is combined
52 with ritonavir-containing antiviral drugs, there is a potential risk of drug-drug
53 interaction. This study aimed to provide guidance on nifedipine treatment during and
54 after co-administration with ritonavir-containing regimens using a physiologically-
55 based pharmacokinetic/pharmacodynamic (PBPK/PD) analysis.

56 **Methods**

57 A PBPK/PD model was developed for nifedipine by the software of Simcyp®, and the
58 model was verified using published data. The effects of ritonavir on nifedipine
59 exposures and systolic blood pressure were assessed for instant-release, sustained-
60 release and controlled-release formulations. Moreover, various nifedipine regimens
61 were investigated when co-administrated with and withdrawing ritonavir.

62 **Results**

63 PBPK/PD models for three formulations of nifedipine were successfully established.
64 The model predicted pharmacokinetic profiles of nifedipine were comparable to the
65 published data. Ratios of predicted versus observed $AUC_{DDI}/AUC_{Nifedipine}$ of nifedipine
66 were within 0.70- to 1.83-fold. Model simulations showed that the inhibitory effect of
67 ritonavir on CYP3A4 increased the C_{max} of nifedipine by 9.82-34.35 times and the AUC
68 by 44.94-50.77 times at steady state. Moreover, nifedipine dose reduced to 1/16 of the
69 regular dose during ritonavir co-administration could lead to severe hypotension.

70 **Conclusions**

71 Ritonavir had a pronounced influence on the pharmacokinetics and antihypertensive
72 effect of nifedipine. It is not recommended for patients to take nifedipine and ritonavir-
73 containing regimens simultaneously.

74

75 **Keywords:** nifedipine, ritonavir, drug-drug interaction, physiologically-based
76 pharmacokinetic, pharmacodynamics

77 **Introduction**

78 The calcium channel blocker (CCB) nifedipine is effective in the treatment of
79 hypertension, angina pectoris and other cardiovascular diseases [1, 2]. European, the
80 United States and Chinese guidelines of hypertension treatment recommend calcium
81 channel blockers (CCB) as the first-line drug therapy [3-5]. The advantages of
82 nifedipine use are rapid onset of action and lack of central nervous system depression.
83 Moreover, comparing to the immediate release (IR) formulation, new once-daily
84 formulations reduce the frequency of nifedipine administration, and thus improve
85 patient compliance. Nifedipine is quickly absorbed after oral administration with peak
86 plasma concentrations occurring in 30 minutes for the IR formulation [6]. It is well
87 absorbed from the gastrointestinal tract, whereas the oral bioavailability of the parent
88 drug is only 45% [7] which suggests that nifedipine undergoes extensive first pass
89 metabolism along the intestine and liver[8, 9]. It is almost completely metabolized by
90 cytochrome P450 (CYP) 3A4 in human body [10]. Therefore, co-administering
91 nifedipine with the strong inhibitors of CYP3A4 may increase its plasma concentrations,
92 leading to the risk of hypotension, hyperglycemia, and conduction disturbances [11].

93 In recent years, viral infections including Human Immunodeficiency Virus (HIV),
94 Severe Acute Respiratory Syndrome coronavirus (SARS-Cov), Middle East
95 Respiratory Syndrome coronavirus (MERS-Cov), and 2019 novel coronavirus (2019-
96 nCoV) have risen as a global threat to public health. Hypertension, the leading risk
97 factor for mortality worldwide, is a growing problem in viral infections patients [12,
98 13]. And many virus-infected patients with hypertension are treated with antiviral and
99 antihypertensive agents concomitantly, such as ritonavir (RTV) -containing regimens
100 and nifedipine.

101 The antiviral drug RTV is a protease inhibitor which can be used as a booster to
102 increase the blood levels of other antiviral medicines including amprenavir, atazanavir,
103 darunavir, fosamprenavir, lopinavir, saquinavir, and tipranavir. Among them,
104 lopinavir/ritonavir (LPV/r) is the most widely used for the treatment of HIV[14] and is
105 regarded as a potential candidate for the treatment of COVID-19 [15-17].

106 RTV is a strong time-dependent inhibitor of CYP3A4. Extensive investigations
107 have proved that RTV has significant influence on the pharmacokinetics of CYP3A4
108 substrates, such as saquinavir[18], quinine[19] and atazanavir[20]. Consequently, co-
109 prescription of these drugs leads to the substantial increase of the blood concentration
110 of CYP3A substrates and increase the risk of adverse drug reactions. Regarding the
111 DDI between nifedipine and RTV, the U.S. Food and Drug Administration (FDA)–
112 approved label states that caution is warranted, clinical monitoring of patients is
113 recommended and a dose decrease may be needed for nifedipine when co-administered
114 with RTV[21]. But the detailed guidance is not provided. Therefore, there is an urgent
115 need to address how to adjust the dose of nifedipine when co-administered with RTV-
116 containing regimens especially during the COVID-19 pandemic.

117 To our knowledge, there have been no reports on DDI between nifedipine and RTV
118 except for a case report[22] which showed that co-administration of nifedipine with
119 RTV may significantly increase nifedipine exposure, leading to severe hypotension and
120 renal failure in a patient with HIV. Therefore, it is risky and costly to investigate the
121 DDI between nifedipine and RTV through traditional clinical trials. While
122 physiologically-based pharmacokinetic (PBPK) models can be of great value for the
123 assessment of the various dose regimens and analysis of the dynamic change in plasma
124 concentrations over time for the victim and inhibitor drugs, and the exploration of the
125 magnitude of DDI[16]. Moreover, PBPK models could link with pharmacodynamic
126 (PD) models to predict changes in drug effect due to extrinsic or intrinsic factors that
127 affect the drug PK[23].

128 The purpose of this study is to investigate the effects of RTV on nifedipine
129 exposure and systolic blood pressure (SBP) via a PBPK/PD modeling approach. And to
130 apply the model to assess various nifedipine dose regimens in the presence or absence
131 of RTV in order to design the regimen for nifedipine during and after co-administration
132 with RTV-containing therapies.

133 **Methods**

134 Nifedipine PBPK model development

135 The PBPK model for nifedipine was built in Simcyp[®] simulator (version 16, Certara
136 Inc., Princeton, New Jersey, USA). Nifedipine is a Biopharmaceutics Classification
137 System Class II drug, with low solubility and high intestinal permeability[24]. It is
138 predominantly eliminated through CYP3A4 metabolism[24, 25]. Nifedipine
139 physicochemical properties (LogP and pKa), absorption, distribution, metabolism and
140 elimination (ADME) parameters are summarized in **Table 1**.

141 The PK profiles for nifedipine were predicted using the Simcyp[®] nifedipine
142 compound file, with a minimal PBPK distribution model and elimination pathway
143 characterized by enzyme kinetics. There are three available nifedipine formulations on
144 the market, namely IR, sustained-release (SR) and controlled-release (CR) formulation.
145 This study investigated all three formulations. The first order model was used to
146 describe the absorption process of nifedipine IR. For the SR and CR nifedipine, the oral
147 absorption was described by the Advanced Dissolution, Absorption and Metabolism
148 (ADAM) model within Simcyp[®] using *in vitro* dissolution data. Dissolution data of the
149 CR and SR formulation were obtained from literature [27] and package insert of
150 Adalat[®][28], respectively.

151

152 Nifedipine PBPK model verification

153 **IR formulation** PBPK model of nifedipine IR was verified using clinical DDI data
154 with CYP3A inhibitors/inducers. The predictive performance of DDI for nifedipine
155 PBPK model was investigated by using the perpetrators of diltiazem and rifampicin,
156 which all have the built in compound files in Simcyp®. Observed data of nifedipine PK
157 from six published DDI studies [1, 2, 29-32] was captured using GetData Graph
158 Digitizer (version 2.22, www.getdata-graph-digitizer.com). Details of these clinical
159 DDI studies were summarized in **Table 2**.

160 **SR and CR formulations** The PBPK models for SR and CR formulations were
161 also verified with PK data from a single-dose administration in healthy volunteers [33,
162 34]. The predicted area under the plasma concentration-time curve (AUC) ratios of
163 nifedipine were compared with the respective observations.

164 The accuracy of prediction was measured by calculating the fold error between
165 predicted and observed, described as (Eq.1). C_{max} and AUC ratios were estimated for
166 all three formulations. Evaluation criteria is the ratio of predicted AUC and C_{max} values
167 are within 2-fold namely, $0.5 \leq \text{ratio} \leq 2.0$ of the observed values.

168
$$\text{Fold error} = \frac{\text{predicted value}}{\text{observed value}} \quad (1)$$

169 Nifedipine-RTV DDI prediction

170 First, the changes of CYP3A4 abundance in liver and intestine with or without RTV
171 were predicted in order to explore the inhibition of RTV on CYP3A4.

172 Then, the established nifedipine PBPK model was used to predict multiple dosing
173 of nifedipine when co-administered with RTV-containing regimens. Since RTV is the
174 only clinical inhibitor and inducer of CYP3A4 within the regimen, only RTV was
175 simulated as a surrogate for the RTV-containing regimens [35]. In addition, the PBPK
176 model of RTV has been already verified by simulating its inhibition effects on the PK
177 profiles of CYP3A4 substrates [36]. Thus, the RTV model was not herein verified.

178 IR nifedipine at 10 mg with repeated dose administration every 12 hours (Q12H)

179 alone was simulated to reach the steady state, followed by the combination of 100 mg
180 Q12H RTV and 10 mg Q12H nifedipine for 14 days. The commonly used regimen for
181 SR and CR formulations 30 mg Q12H and 60 mg every 24 hours (Q24H), respectively
182 were also simulated. Considering no consensus for the use of nifedipine in patients
183 receiving RTV, PK profiles at different dose levels of nifedipine was simulated to
184 investigate the optimal dose during the co-administration with RTV.

185 After RTV was discontinued, 2 different dose regimens were investigated. One is
186 to use reduced-dose nifedipine, and the other is to restore to the original dose of
187 nifedipine. Taking IR tablets as an example, in the first regimen, nifedipine at a lower
188 dose (5 mg Q12H) or an extended dosing interval (10 mg Q24H) was taken for 5 more
189 days after the last dose of RTV, followed by a return to an original regimen (10 mg
190 Q12H). Moreover, lower dose of nifedipine (1.25 mg, 1/4 of the minimum specification
191 of IR nifedipine tablets) was investigated. Since chewing or crushing before swallowing
192 SR or CR tablets is not allowed, dose less than 30 mg or 60 mg was not assessed. In the
193 second regimen, the regular dose of nifedipine (10 mg Q12H) was taken immediately
194 after the last dose of RTV. The detailed dose adjustment scenarios are shown in **Table**
195 **3**. Due to the limitation of software, the dose amount of SR and CR tablets cannot be
196 adjusted directly and only the adjustment of the dosing interval was assessed.

197 Nifedipine PD model development and verification

198 Studies have demonstrated that it is more important to control systolic blood
199 pressure (SBP) than diastolic blood pressure (DBP)[37], and SBP is a better predictor
200 of cardiovascular risk than DBP in most of patients treated with antihypertensive
201 agents[38]. Therefore, only SBP was employed in the PBPK/PD modeling. A E_{max}
202 model developed by Shimada *et al.*[39] was linked to the PBPK to investigate the effect
203 of DDI on the SBP. The relationship between nifedipine concentration and the reduction
204 in SBP was expressed by ordinary E_{max} model (Eq. 2).

$$205 \quad E = \frac{E_{max}C}{EC_{50}+C} \quad (2)$$

206 where E, E_{max} , EC_{50} and C represent the reduction in SBP, the maximum reduction in

207 SBP, nifedipine concentration at 50% maximum effect and nifedipine concentration,
208 respectively.

209 The E_{max} and the EC_{50} were -35 mmHg and 35 nM for therapeutic dose in the
210 previous report, respectively[39]. However, in reported cases of nifedipine overdose,
211 the SBP of the patients would decrease about 50 mmHg [6, 40, 41]. Therefore, in this
212 study, the E_{max} value was increased to -50 mmHg to fit the maximal SBP decrease based
213 on the previous case reports of nifedipine overdose. In addition, based on the range of
214 EC_{50} values reported in the literature [39, 42], PD model under different EC_{50} values
215 was examined to fit the observed SBP change caused by nifedipine at therapeutics doses
216 [43, 44]. Details of these clinical PD studies were summarized in **Table 4**. The accuracy
217 of prediction was measured by comparing the maximum reduction in SBP (R_{max}) and
218 the area under the effect-time curve (AUE) between prediction and observation. The
219 acceptable criteria were within 2-fold error.

220 Nifedipine PBPK/PD model application

221 The developed PBPK/PD model was used to predict the changes in SBP caused by the
222 dynamic changes in nifedipine exposures with and without RTV. Two clinical scenarios
223 were simulated and all the model simulations were carried out using a virtual population
224 representative within Simcyp[®].

225 The first scenario was designed to answer whether dose adjustment of nifedipine
226 can maintain SBP at normal range. Two dosing regimens were investigated after
227 patients taking combined nifedipine with RTV at steady state, (1) the nifedipine dose
228 was continued at regular regimen during co-administration with RTV; (2) the nifedipine
229 regimen was changed to extended dosing interval during the co-administration with
230 RTV.

231 The second scenario was designed to investigate how to adjust the dose regimen of
232 nifedipine after the withdrawal of RTV. For this scenario, two dosing regimens were
233 examined, (1) adjusted dosage regimen was continued for 5 more days after the last
234 dose of RTV; (2) the regular regimen was resumed immediately after RTV was stopped.

235 **Results**

236 Development of the nifedipine PBPK model

237 The model of IR nifedipine was developed first using the Simcyp[®] compound file. Next
238 was development of the SR and CR nifedipine model which used the same input data
239 as the IR model except for the absorption model and dissolution data. The IR nifedipine
240 used the first-order absorption model, while the SR and CR formulations used the
241 ADAM model.

242 Verification of the nifedipine PBPK model

243 Concentration–time plasma profiles from DDI studies were used to verify the PK model
244 of nifedipine. The PBPK model predictions of nifedipine plasma concentrations profiles
245 in three formulations (IR/SR/CR) were consistent with the clinically observed data and
246 met the model acceptance criteria. The detailed results are as follows:

247 **IR formulation** Using 6 published DDI studies[1, 2, 29-32], the predicted AUC
248 and C_{max} ratios of nifedipine after single or multiple administrations in the presence and
249 absence of concomitant drugs were compared with the respective observations (**Table**
250 **5; Figure 1-2**). The results show that the predicted nifedipine AUC values in the
251 absence of concomitant drugs were consistent with observed data, and median fold-
252 error was 0.66 (range: 0.29-1.84). In the presence of concomitant drugs, the predicted
253 $AUC_{DDI}/AUC_{Nifedipine}$ value was within 0.70-1.83-fold of the observed
254 $AUC_{DDI}/AUC_{Nifedipine}$ value. Relatively good predictability of the C_{max} ratios within 0.5-
255 2-fold was also confirmed, in comparison with the respective clinical observations.
256 Thus, the current nifedipine model demonstrated good performance for the purpose of
257 DDI investigation.

258 **SR formulation** As shown in **Figure 3**, the PBPK model for SR formulation
259 resulted in a good agreement between observed and predicted values for nifedipine PK
260 profiles after single oral dose administration in the healthy volunteers. And the

261 predicted AUC ratio was 1.45-fold of the observed AUC which indicated good
262 predictive performance.

263 **CR formulation** **Figure 4** shows the observed and predicted values for CR
264 nifedipine PK profiles after a single oral dose administration in the healthy volunteers.
265 The predicted C_{max} and AUC ratios were within 1.46-fold of the observed data.
266 Therefore, the PBPK model for CR formation showed a good descriptive and predictive
267 performance.

268 Nifedipine-RTV DDI

269 The final PBPK model was used to predict changes in CYP3A4 enzyme abundance and
270 nifedipine plasma PK profiles after the co-administration with RTV over time. As
271 shown in **Figure 5**, the CYP3A4 in the liver and intestinal were maximally deactivated
272 within three days after the co-administration of RTV (100 mg Q12H), which suggested
273 there was a strong DDI between nifedipine and RTV. **Figure 6** shows the predicted PK
274 profiles of three formulations nifedipine over time following the dosing schedules listed
275 in **Table 3**. Both the C_{max} and AUC increased significantly due to CYP3A4 inhibition
276 by RTV and reached steady state on approximately Day 10. The inhibitory effect of
277 RTV on CYP3A4 increased the C_{max} of nifedipine by 9.82-34.35 times and the AUC_{24h}
278 by 44.94-50.77 times (**Table 6**), which showed that the combination of RTV have a
279 significant impact on the exposure of nifedipine.

280 Moreover, the plasma concentration of three formulations of nifedipine decreased
281 to the baseline (without RTV) on the 4-5th day after the last dose of RTV.

282 Verification of the nifedipine PD model

283 When the EC_{50} was set to 98 nM, the PD model fitted best. The model-predicted SBP
284 compared with the observations for nifedipine at regular dose were presented in **Figure**
285 **7**. And the predicted PD profiles for three formulations nifedipine at regular doses
286 suggested that the model was successful in predicting the clinical data. The ratios of the
287 predicted and observed values of R_{max} and AUE for IR, SR and CR nifedipine were

288 within 0.87-1.14 (**Table 7**). Thus, the current nifedipine PD model showed good
289 predictive performance.

290 Nifedipine-RTV PBPK/PD model application

291 For the three formulations of nifedipine, dose adjustment of nifedipine during RTV co-
292 administration was unable to maintain nifedipine plasma concentrations and SBP at the
293 same level as without RTV (**Figure 8**). Moreover, the established PBPK model showed
294 that reducing the daily dose of IR nifedipine from 20 to 1.25 mg did not significantly
295 alter the nifedipine-RTV DDI potential, suggesting that reduced-dose (1/16) nifedipine
296 (**Figure S1**) might not fully mitigate the risk of severe hypotension when combined
297 with standard-dose (100 mg) RTV. The influence of dose reduction on the SR and CR
298 formulations are the same as IR.

299 For scenario 1, **Figure 9** shows the PD profiles of regular dose of nifedipine
300 combined with RTV. For an individual taking a regular nifedipine dose combined with
301 100 mg Q12H RTV, the predicted dynamic SBP decrease was up to 47 mmHg, which
302 might be a critically low blood pressure. Moreover, nifedipine at a reduced dose during
303 RTV co-administration was unable to maintain SBP in normal range (**Figure 10**).
304 Therefore, the combined use of nifedipine and RTV-containing regimens is not
305 recommended.

306 The simulations from scenarios 2 (**Figure 10**) showed continuing the reduced
307 nifedipine dose for an additional 5 days results in a lower nifedipine plasma
308 concentrations and a corresponding increase in SBP over the 5 days. This suggested
309 that the dose of nifedipine cannot be immediately restored to the regular dose after the
310 withdrawal of RTV in case of RTV co-administration.

311 **Discussion**

312 With the outbreak of viral infections such as COVID-19, MERS and SARS, the antiviral
313 effect of RTV-containing regimens has received increasing attention [16, 45].
314 Hypertensive patients are often potential susceptible population [46, 47] and require

315 antiviral treatment after viral infection. Thus, the combination of CCB and RTV is not
316 unavoidable. There have been previous studies [35, 48] on the DDI of RTV and
317 amlodipine, but there is a lack of systematic research on the commonly used CCB,
318 nifedipine. To the best of our knowledge, this is the first systematic study to investigate
319 the DDI between nifedipine and RTV-containing regimens by using PBPK/PD analysis.

320 Previously published PBPK modeling of nifedipine mainly focused on the drug
321 formulations [23, 49] or special populations [50-52]. The nifedipine model developed
322 in this study is more comprehensive considering commonly used three formulations,
323 relationship of PK and PD and DDI. Moreover, the nifedipine PBPK model built in the
324 software of Simcyp® hasn't been well verified for the purpose of DDI prediction. The
325 developed nifedipine model was herein verified with clinical DDI studies involving
326 CYP3A inhibitors/inducers or with PK profiles from the healthy volunteers. Although
327 the absolute values of the model-predicted C_{max} and AUC did not match the observed
328 values perfectly, the exposure change caused by DDI were in good agreement with the
329 observed data (all the fold errors <1.83) (**Table 4**). This indicates the good performance
330 of nifedipine PBPK model as a victim drug in the DDI prediction.

331 Nifedipine undergoes significant first-pass metabolism by CYP3A in the both
332 intestine and liver[53], thus resulting in significantly enhanced *in vivo* exposure of the
333 drug when administered together with strong irreversible CYP3A4 inhibitor like RTV.
334 The inhibitory potency of RTV *in vivo* has been shown to be equivalent to or greater
335 than ketoconazole which is a strong index CYP3A inhibitor for DDI studies [54]. The
336 PBPK model described the interaction over time between nifedipine and RTV, and
337 showed that the combined use of RTV significantly reduced the CYP3A4 enzyme
338 content in the liver and intestine and the C_{max} and AUC_{24h} of nifedipine increased by
339 9.82-34.35 and 44.94-50.77 times, respectively. The C_{max} of all three formulations
340 nifedipine exceeded 700 ng/ml, which is far beyond the therapeutic concentration range
341 of nifedipine (25-100 ng/mL)[6]. Therefore, the potential risk of severe hypotension
342 becomes very high after its combined use with RTV.

343 Moreover, the established PBPK/PD model showed that nifedipine dose reduced
344 to 1/16 of the regular dose during RTV co-administration couldn't prevent the risk of

345 hypotension. Therefore, patients are not recommended to take any formulations of
346 nifedipine and RTV-containing regimens simultaneously. In addition, it takes 5 days of
347 wash-out after RTV withdrawal to allow the nifedipine concentration to drop down to
348 a safe level when patient taking nifedipine. These results are the important hints for
349 patients taking the nifedipine treatment.

350 The PBPK/PD analysis was once used to investigate dose adjustment
351 recommendations for amlodipine during and after co-administration of RTV by
352 Mukherjee, *et al* [35]. The analysis suggested that resuming a full dose of amlodipine
353 (5 mg QD) immediately or continuing with the reduced dose (2.5 mg QD) for 5 days
354 after the last dose of RTV could be appropriate. Based on the simulation of this study,
355 the effect of RTV on nifedipine PK is significantly stronger than that on amlodipine,
356 although nifedipine and amlodipine are both dihydropyridine CCBs. Compared with
357 nifedipine, amlodipine has a lower incidence of interactions due to less first-pass
358 metabolism[55]by CYP3A isoform in the intestine and liver.

359 This study systematically investigated the DDI between nifedipine and RTV-
360 containing regimens, and provided meaningful guidance for clinical use, especially
361 during the COVID-19 pandemic. The recent open-label, randomized, phase 2 trial in
362 patients with COVID-19 showed that triple combinations of interferon beta-1b, LPV/r
363 and ribavirin was safe and superior to LPV/r alone in alleviating symptoms and
364 shortening the duration of viral shedding and hospital stay in patients with mild to
365 moderate COVID-19[17]. And it's reported that among 5700 patients hospitalized with
366 COVID-19 in the New York City area, even up to 56.6% have comorbid hypertension
367 [56]. Thus, the scenario of combining RTV during nifedipine drug treatment would
368 probably be of great clinical relevance. Our study showed that it could lead to severer
369 hypotension for patients with COVID-19 to take nifedipine and RTV-containing
370 regimens simultaneously.

371 Due to the lack of pharmacodynamic studies of nifedipine overdose, PD model in
372 this study referred to the previously reported model and verified with clinical data at
373 therapeutic doses, which may not accurately predict blood pressure changes at
374 excessive dose. However, the exposure of nifedipine regardless of the formulation has

375 increased many times after the combined use of RTV, far beyond the normal range.
376 Therefore, the combined use of nifedipine and RTV-containing regimens is still not
377 recommended according to PK prediction results. If an antiviral regimen containing
378 RTV is required, other antihypertensive agents should be replaced.

379 **Conclusions**

380 RTV had a pronounced effect on the pharmacokinetics of nifedipine. Combinations of
381 nifedipine and RTV is not recommended according to the PBPK/PD analysis. Restart
382 of nifedipine 5 days after discontinuation of RTV can maintain plasma levels and blood
383 pressure at a relatively safe level.

384

385

Table list

Table 1 The parameters included in the PBPK model for nifedipine.

Parameter	Units	Values
molecular weight	g/mol	346.3*
LogP	-	2.69*
pKa	-	2.82* (monoprotic base)
f_u	-	0.039*
B/P ratio	-	0.685*
Absorption model		ADAM (SR, CR) 1st order(IR)
MDCK II permeability	cm/s	61×10^{-6} (IR,SR)[26]
$P_{\text{eff,man}}$ in colon	cm/s	0.17×10^{-4} (CR)[27]
f_a	-	1* (IR)
k_a	1/h	3.67* (IR)
Distribution model		Minimal PBPK
V_{ss}	L/kg	0.57*
Elimination		
rCYP3A4		
K_m	μM	10.95*
V_{max}	pmol/min/pmol CYP	22*
rCYP3A5		
K_m	μM	31.9*
V_{max}	pmol/min/pmol CYP	3.5*

*: obtained by SimCYP® simulator (version 16)

ADAM, the Advanced Dissolution, Absorption and Metabolism model; B/P ratio, blood to plasma concentration ratio; CR, controlled release; ; f_a , fraction available from dosage form; f_u , the fraction unbound in plasma; IR, immediate release; k_a , absorption rate constant; K_m , the Michaelis-Menten constant; LogP, octanol–water partition; Minimal PBPK, Minimal Physiologically-based Pharmacokinetic model; $P_{\text{eff,man}}$, the effective permeability in humans; SR, sustained release; V_{max} , the maximal enzyme velocity; V_{ss} , volume of distribution at steady-state.

Table 2 Summary of published clinical DDI studies used for verifying the nifedipine PBPK model.

Study	Route of administration	Dose	Information	References
CYP3A inhibitors				
diltiazem	oral	nifedipine 20 mg + diltiazem 60 mg	Effect of duration of diltiazem pretreatment on nifedipine kinetics	Ohashi et al. [29]
	oral	I. nifedipine 20 mg + diltiazem 30 mg II. nifedipine 20 mg + diltiazem 90 mg	Dose dependent effect of diltiazem on the PK of nifedipine	Tateishi et al.[30]
	oral	diltiazem 60 mg TID ×3 days + nifedipine 20 mg	Effects of diltiazem on the PK of nifedipine	Ohashi et al. [31]
CYP3A inducer				
rifampicin	oral IV	rifampicin 600 mg QD 7 days + nifedipine 20 mg rifampicin 600 mg QD 7 days + nifedipine 20 µg/kg	Nifedipine-rifampin interaction	Holtbecker et al.[32]
	oral	rifampicin 1200 mg+ nifedipine 10 mg (administered 8 h after treatment of rifampicin)	Effect of single dose of rifampicin on the PK of nifedipine	Ndanusa et al. [1]

TID, three times a day; *Q8H*, every 8 hours; *QD*, once daily; *IV*, intravenous; *PK*, pharmacokinetic; *PD*, pharmacodynamics

Table 3 Clinical scenarios used in the nifedipine PBPK model simulation.

Nifedipine formulation	Combined with RTV	After withdrawal of RTV	
		Nifedipine regimen 1	Nifedipine regimen 2
Immediate Release (IR)	I. 10 mg Q12H × 3 days + (5 mg Q12H + RTV 100 mg Q12H) × 14 days	5 mg Q12H × 5 days + 10 mg Q12H	10 mg Q12H
	II. 10 mg Q12H × 3 days + (10 mg Q24H + RTV 100 mg Q12H) × 14 days	10 mg Q24H × 5 days + 10 mg Q12H	10 mg Q12H
	III. 10 mg Q12H × 3 days + (1.25 mg Q12H + RTV 100 mg Q12H) × 14 days	1.25 mg Q12H × 5 days + 10 mg Q12H	10 mg Q12H
	IV. 10 mg Q12H × 3 days + (1.25 mg Q24H + RTV 100 mg Q12H) × 14 days	1.25 mg Q24H × 5 days + 10 mg Q12H	10 mg Q12H
Sustained Release (SR)	30 mg Q12H × 3 days + (30 mg Q24H + RTV 100 mg Q12H) × 14 days	30 mg Q24H × 5 days + 30 mg Q12H	20 mg Q12H
Controlled Release (CR)	60 mg Q24H × 3 days + (60 mg Q48H + RTV 100 mg Q12H) × 14 days	60 mg Q48H × 5 days + 60 mg Q24H	60 mg Q24H

Q12H, every 12 hours; *Q24H*, every 24 hours; *Q48H*, every 48 hours; *RTV*, ritonavir.

Table 4 Summary of published clinical PD studies used for verifying the nifedipine PD model.

Study	Dose (mg)	Information	References
Immediate-Release (IR) nifedipine	10	Effect of food ingestion on nifedipine haemodynamic response (A 10mg nifedipine capsule was administered orally 30 min before breakfast)	Hirasawa et al.[43]
Sustained-Release (SR) nifedipine	20	The haemodynamic responses to nifedipine administered orally in different formulations to hypertensive patients	Meredith et al.[44]
Controlled-Release (CR) nifedipine	60		

Table 5 Comparison of IR formulation PBPK model predicted and clinically observed pharmacokinetic parameter.

Clinical DDI study	PK parameter	Without Concomitant drug			With Concomitant drug		$\frac{PK_{DDI}}{PK_{Nifedipine}}$		
		Pred	Obs	Fold error	Pred	Obs	Pred	Obs	Fold error
diltiazem + nifedipine[29]	AUC _{0-∞} (ng·h/mL)	360.09	680±135	0.53	404.30	905±197	1.22	1.33	0.92
		348.76	809±318	0.43	1176.98	1941±577	2.37	2.40	0.99
		447.68	579±191	0.77	1471.27	1711±857	3.29	2.96	1.11
diltiazem + nifedipine[30]	AUC _{0-∞} (ng·h/mL)	392.04	597.9±52.4	0.66	755.15	1329.1±515.5	1.93	2.22	0.87
	C _{max} (ng/mL)	131.18	236.0±70.7	0.56	184.16	473.9±85.6	1.40	2.01	0.70
	AUC _{0-∞} (ng·h/mL)	392.04	597.9±52.4	0.66	1513.37	1329.1±515.5	3.86	3.11	1.24
	C _{max} (ng/mL)	131.18	236.0±70.7	0.56	243.94	404.0±22.4	1.86	1.71	1.09
diltiazem + nifedipine [31]	AUC _{0-∞} (ng·h/mL)	369.35	453.65±176.61	0.81	1125.33	1087.38±322.06	3.05	2.4	1.27
	C _{max} (ng/mL)	122.26	412±177	0.30	210.88	516±137	1.72	1.25	1.38
rifampicin + nifedipine[32]	AUC _{i.v.} (ng·h/mL)	70.40	38.1±4.8	1.84	34.22	26.7±12.0	0.49	0.7	0.70
	AUC _{p.o.} (ng·h/mL)	391.37	229.9±33.8	1.70	58.82	18.8±8.6	0.15	0.082	1.83
rifampicin + nifedipine[1]	AUC _{0-∞} (ng·h/mL)	166.45	572.40±14.0	0.29	53.00	204.92±0.0	0.318	0.358	0.89
	C _{max} (ng/mL)	64.20	173.2±6.1	0.37	27.99	115.77±7.6	0.44	0.67	0.65

$$* \text{ Pred: Obs ratio} = \frac{\text{Pred} \frac{AUC_{DDI}}{AUC_{Nifedipine}}}{\text{Obs} \frac{AUC_{DDI}}{AUC_{Nifedipine}}} \text{ or } = \frac{\text{Pred} \frac{C_{max_{DDI}}}{C_{max_{Nifedipine}}}}{\text{Obs} \frac{C_{max_{DDI}}}{C_{max_{Nifedipine}}}}$$

AUC, area under the plasma concentration-time curve; C_{max}, the maximum concentration; DDI, drug-drug interaction; Obs, observation; Pred, prediction, Fold-error, ratio of predicted: observed values.

Table 6 A summary of PK parameters of nifedipine after co-administration with RTV using the final PBPK model.

Parameter	IR formulation		SR formulation		CR formulation	
	nifedipine	nifedipine + RTV	nifedipine	nifedipine + RTV	nifedipine	nifedipine + RTV
T_{max} (h)	4.14	8.15	8.57	12.23	8.34	9.68
C_{max} (ng/mL)	65.79	745.86	42.11	1241.12	41.48	1683.39
AUC _{24h} (ng/mL·h)	275.80	16053.90	508.03	28109.70	694.79	38534.48
C_{max} Ratio ($\frac{nifedipine + RTV}{nifedipine}$)		9.82		28.71		34.35
AUC Ratio ($\frac{nifedipine + RTV}{nifedipine}$)		50.77		49.58		44.94

AUC, area under the plasma concentration-time curve; C_{max} , the maximum concentration; *CR*, controlled release; *IR*, immediate release; *RTV*, ritonavir; *SR*, sustained release; T_{max} , time to reach maximum plasma concentration.

Table 7 Comparison of the predicted and observed maximum reduction in systolic blood pressure (R_{\max}) and the area under the effect-time curve (AUE) for the different nifedipine formulations.

	Immediate-Release (IR) nifedipine			Sustained-Release (SR) nifedipine			Controlled-Release (CR) nifedipine		
	Pred	Obs	Fold error	Pred	Obs	Fold error	Pred	Obs	Fold error
R_{\max} (mmHg)	-32.93	-33.2	0.99	-26.35	-23.04	1.14	-23.61	-23.18	1.02
AUE (mmHg·h)	88.33	102	0.87	196.6	195	1.01	428.4	435.4	0.98

Obs, observation; *Pred*, prediction, *Fold-error*, ratio of predicted: observed values.

Figure list

Figure 1 Comparison of PBPK model predictions of plasma concentrations of IR formulation nifedipine. Panel A-F give predicted PK profiles of nifedipine in the presence (red dotted lines) and absence (black lines) of diltiazem. The green circles and blue triangles represented the observed nifedipine concentration in the presence and absence of concomitant drugs, respectively. (A) nifedipine 20 mg + diltiazem 60 mg; (B) nifedipine 20 mg + diltiazem 60 mg Q8H×10 doses; (C) nifedipine 20 mg + diltiazem 60 mg Q8H×19 doses; (D) nifedipine 20 mg + diltiazem 30 mg; (E) nifedipine 20 mg + diltiazem 90 mg; (F) nifedipine 20 mg + diltiazem 60 mg TID ×3 days.




Figure 2 Comparison of PBPK model predictions of plasma concentrations of IR formulation nifedipine. Panel A-C give predicted PK profiles of nifedipine in the presence (red dotted lines) and absence (black lines) of rifampicin. The green circles and blue triangles represented the observed nifedipine concentration in the presence and absence of concomitant drugs, respectively. (A) rifampicin 600 mg QD 7 days + nifedipine 20 μ g/kg, infusion; (B) rifampicin 600 mg QD 7 days + nifedipine 20 mg, oral; (C) rifampicin 1200 mg, nifedipine 10 mg (administered 8 h after pre-treatment of rifampicin.).




Figure 3 Comparison of physiologically-based pharmacokinetic (PBPK) model predictions (black lines) of plasma concentrations of SR formulation nifedipine in healthy volunteers with 20 mg single dose. Clinical data is represented as red circles.




Figure 4 Comparison of physiologically-based pharmacokinetic (PBPK) model predictions (black lines) of plasma concentrations of CR formulation nifedipine in healthy volunteers after a 60 mg oral dose. Clinical data is represented as red circles.




Figure 5 Predictions of active CYP3A4 abundance profiles in (A) liver and (B) intestinal over time after multiple oral administration of ritonavir. The red and black solid lines represent the concentration curves of combined nifedipine with RTV and nifedipine alone, respectively.




Figure 6 Model prediction of time-based changes in the drug–drug interaction (DDI) magnitude of nifedipine and ritonavir (RTV) over multiple days. (A) IR nifedipine 10 mg every 12 hours (Q12H) \times 3 days + (nifedipine 10 mg Q12H + RTV 100 mg Q12H) \times 14 days+ nifedipine 10 mg Q12H \times 10 days. (B) SR nifedipine 30 mg Q12H \times 3 days + (30 mg Q12H +RTV 100 mg Q12H) \times 14 days+ nifedipine 30 mg Q12H \times 10 days. (C) CR nifedipine 60 mg Q24H \times 3 days+ (60 mg Q24H + RTV 100 mg Q12H) \times 14 days+ nifedipine 60 mg Q24H \times 10 days. The red and blue solid lines represent the concentration curves of combined nifedipine with RTV and nifedipine alone, respectively.




Figure 7 Comparison of model predicted systolic blood pressure (SBP) compared with clinical observations in patients after a single dose of (A) 10 mg IR nifedipine; (B) 20mg SR nifedipine; (C) 60 mg CR nifedipine. Red circles represent observed values and black line represent predicted values.




Figure 8 PK simulation results of nifedipine dose adjustment in different scenarios after RTV discontinuation. (A) IR nifedipine 10 mg every 12 hours (Q12H) × 3 days + (5 mg Q12H + RTV 100 mg Q12H) × 14 days+ nifedipine 5 mg Q12H ×5 days + nifedipine 10 mg Q12H × 1 day. (B) IR nifedipine 10 mg Q12H × 3 days + (5 mg Q12H + RTV 100 mg Q12H) ×14 days+ nifedipine 10 mg Q12H × 6 days. (C) IR nifedipine 10 mg Q12H × 3 days + (10 mg Q24H + RTV 100 mg Q12H) ×14 days + nifedipine 10 mg Q24H × 5 days + nifedipine 10 mg Q12H × 1 day. (D) IR nifedipine 10 mg Q12H × 3 days + (10 mg Q24H + RTV 100 mg Q12H) ×14 days+ nifedipine 10 mg Q12H × 6 days. (E) SR nifedipine 30 mg Q12H × 3 days + (30 mg Q24H + RTV 100 mg Q12H) × 14 days + nifedipine 30 mg Q24H × 5 days + nifedipine 30 mg Q12H × 1 day. (F) SR nifedipine 30mg Q12H × 3 days + (30 mg Q24H + RTV 100 mg Q12H) × 14 days + nifedipine 30 mg Q12H × 6 day. (G) CR nifedipine 60 mg Q24H × 3 days + (60 mg Q48H + RTV 100 mg Q12H) × 14 days + nifedipine 60 mg Q24H × 5 days + nifedipine 60 mg Q24H × 1 day. (H) CR nifedipine 60 mg Q24H × 3 days + (60 mg Q48H + RTV 100 mg Q12H) ×14 days + nifedipine 60 mg Q24H × 6 days. Red and blue lines represent predicted values for nifedipine with and without co-administration of RTV, respectively.




Figure 9 Model prediction of SBP changes in the drug–drug interaction (DDI) magnitude of nifedipine and ritonavir (RTV) over multiple days. (A) IR nifedipine 10 mg every 12 hours (Q12H) \times 3 days + (nifedipine 10 mg Q12H + RTV 100 mg Q12H) \times 14 days+ nifedipine 10 mg Q12H \times 10 days. (B) SR nifedipine 30 mg Q12H \times 3 days + (30 mg Q12H +RTV 100 mg Q12H) \times 14 days+ nifedipine 30 mg Q12H \times 10 days. (C) CR nifedipine 60 mg Q24H \times 3 days+ (60 mg Q24H + RTV 100 mg Q12H) \times 14 days+ nifedipine 60 mg Q24H \times 10 days. The red and black solid lines represent the PD curves of combined nifedipine with RTV and nifedipine alone, respectively.






Figure 10 PD simulation results of nifedipine dose adjustment in different scenarios after RTV discontinuation. (A) IR nifedipine 10 mg every 12 hours (Q12H) \times 3 days + (5 mg Q12H + RTV 100 mg Q12H) \times 14 days+ nifedipine 5 mg Q12H \times 5 days + nifedipine 10 mg Q12H \times 1 day. (B) IR nifedipine 10 mg Q12H \times 3 days + (5 mg Q12H + RTV 100 mg Q12H) \times 14 days+ nifedipine 10 mg Q12H \times 6 days. (C) IR nifedipine 10 mg Q12H \times 3 days + (10 mg Q24H + RTV 100 mg Q12H) \times 14 days + nifedipine 10 mg Q24H \times 5 days + nifedipine 10 mg Q12H \times 1 day. (D) IR nifedipine 10 mg Q12H \times 3 days + (10 mg Q24H + RTV 100 mg Q12H) \times 14 days+ nifedipine 10 mg Q12H \times 6 days. (E) SR nifedipine 30 mg Q12H \times 3 days + (30 mg Q24H + RTV 100 mg Q12H) \times 14 days + nifedipine 30 mg Q24H \times 5 days + nifedipine 30 mg Q12H \times 1 day. (F) SR nifedipine 30mg Q12H \times 3 days + (30 mg Q24H + RTV 100 mg Q12H) \times 14 days + nifedipine 30 mg Q12H \times 6 day. (G) CR nifedipine 60 mg Q24H \times 3 days + (60 mg Q48H + RTV 100 mg Q12H) \times 14 days + nifedipine 60 mg Q24H \times 5 days + nifedipine 60 mg Q24H \times 1 day. (H) CR nifedipine 60 mg Q24H \times 3 days + (60 mg Q48H + RTV 100 mg Q12H) \times 14 days + nifedipine 60 mg Q24H \times 6 days. The open square symbols correspond to the mean observed values. Red and black lines represent predicted values for nifedipine with and without co-administration of RTV, respectively.



Supplementary Figure 1 PK (A, B) and PD (C, D) simulation results of IR nifedipine dose adjustment in following scenarios after RTV discontinuation. (A)(C) 10 mg Q12H \times 3 days + (1.25 mg Q12H + RTV 100 mg Q12H) \times 14 days + 1.25 mg Q12H \times 5 days + 10 mg Q12H; (B)(D) 10 mg Q12H \times 3 days + (1.25 mg Q24H + RTV 100 mg Q12H) \times 14 days + 1.25 mg Q24H \times 5 days + 10 mg Q12H.



Reference

1. Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single doses of rifampicin on the pharmacokinetics of oral nifedipine. *J Pharm Biomed Anal.* 1997;15:1571-5.
2. Bowles SK, Reeves RA, Cardozo L, Edwards DJ. Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. *Journal of clinical pharmacology.* 1993;33:727-31.
3. Liu L. 2018 Chinese guidelines for the management of hypertension. *Chinese Journal of Cardiovascular Medicine.* 2019;24:25.
4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *European heart journal.* 2018;39:3021-104.
5. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology.* 2018;71:2199-269.
6. Haddad LM. Resuscitation after nifedipine overdose exclusively with intravenous calcium chloride. *The American journal of emergency medicine.* 1996;14:602-3.
7. Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. *Journal of clinical pharmacology.* 1983;23:161-70.
8. Iwao T, Inoue K, Hayashi Y, Yuasa H, Watanabe J. Metabolic extraction of nifedipine during absorption from the rat small intestine. *Drug metabolism and pharmacokinetics.* 2002;17:546-53.
9. Yang W, Otto DP, Liebenberg W, de Villiers MM. Effect of para-sulfonato-calix[n]arenes on the solubility, chemical stability, and bioavailability of a water insoluble drug nifedipine. *Current drug discovery technologies.* 2008;5:129-39.
10. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. *The Journal of biological chemistry.* 1986;261:5051-60.
11. Welch RD, Todd K. Nifedipine overdose accompanied by ethanol intoxication in a patient with congenital heart disease. *The Journal of emergency medicine.* 1990;8:169-72.
12. Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. *Hypertens Res.* 2020:1-3.
13. Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-Infected Adults: Novel Pathophysiologic Mechanisms. *Hypertension (Dallas, Tex : 1979).* 2018;72:44-55.
14. Hughes PJ, Cretton-Scott E, Teague A, Wensel TM. Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview. *P & T : a peer-reviewed journal for formulary management.* 2011;36:332-45.
15. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 3). National Health Commission of the People's

- Republic of China; [cited 2020 March 25]; Available from: <http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml>
16. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. *Journal of medical virology*. 2020.
 17. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet*. 2020.
 18. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. *Clinical pharmacology and therapeutics*. 1998;63:453-64.
 19. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. *British journal of clinical pharmacology*. 2010;69:262-70.
 20. Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, et al. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. *British journal of clinical pharmacology*. 2012;74:336-45.
 21. Abbott Laboratories. Norvir (ritonavir) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_prntlbl.PDF Accessed May 4, 2020.
 22. Baeza MT, Merino E, Boix V, Climent E. Nifedipine-lopinavir/ritonavir severe interaction: a case report. *AIDS (London, England)*. 2007;21:119-20.
 23. Chetty M, Rose RH, Abduljalil K, Patel N, Lu G, Cain T, et al. Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. *Frontiers in pharmacology*. 2014;5:258.
 24. Nader AM, Quinney SK, Fadda HM, Foster DR. Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine. *The AAPS journal*. 2016;18:981-8.
 25. Khan KM, Patel J, Schaefer TJ. Nifedipine. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
 26. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. *The Journal of pharmacology and experimental therapeutics*. 2001;299:620-8.
 27. Doki K, Darwich AS, Patel N, Rostami-Hodjegan A. Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2017;109:111-20.
 28. Nipro Pharmaceutical Companies, Nifedipine [package insert]. Pharmaceuticals and Medical Devices Agency (PMDA); [cited 2020 5.16]; Available from: <http://med.nipro.co.jp/servlet/servlet.FileDownload?file=0151000000KJvaAAG>.
 29. Ohashi K, Sudo T, Sakamoto K, Tateishi T, Fujimura A, Kumagai Y, et al. The influence of

- pretreatment periods with diltiazem on nifedipine kinetics. *Journal of clinical pharmacology*. 1993;33:222-5.
30. Tateishi T, Ohashi K, Sudo T, Sakamoto K, Toyosaki N, Hosoda S, et al. Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. *Journal of clinical pharmacology*. 1989;29:994-7.
31. Ohashi K, Tateishi T, Sudo T, Sakamoto K, Toyosaki N, Hosoda S, et al. Effects of diltiazem on the pharmacokinetics of nifedipine. *J Cardiovasc Pharmacol*. 1990;15:96-101.
32. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. *Drug metabolism and disposition: the biological fate of chemicals*. 1996;24:1121-3.
33. Toal CB, Meredith PA, Elliott HL. Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses. *Int J Clin Pharmacol Ther*. 2012;50:202-17.
34. Kleinbloesem CH, van Harten J, Wilson JP, Danhof M, van Brummelen P, Breimer DD. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. *Clinical pharmacology and therapeutics*. 1986;40:21-8.
35. Mukherjee D, Zha J, Menon RM, Shebley M. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. *Journal of pharmacokinetics and pharmacodynamics*. 2018;45:443-56.
36. Umehara KI, Huth F, Won CS, Heimbach T, He H. Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates. *Biopharmaceutics & drug disposition*. 2018;39:152-63.
37. Levine CB, Fahrback KR, Frame D, Connelly JE, Estok RP, Stone LR, et al. Effect of amlodipine on systolic blood pressure. *Clinical therapeutics*. 2003;25:35-57.
38. Mourad JJ. The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target. *Vascular health and risk management*. 2008;4:1315-25.
39. Shimada S, Nakajima Y, Yamamoto K, Sawada Y, Iga T. Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. *Biol Pharm Bull*. 1996;19:430-7.
40. Zhou H, Liu Y, Li GQ, Wei LQ. A novel dosing regimen for calcium infusion in a patient of massive overdose of sustained-release nifedipine. *The American journal of the medical sciences*. 2013;345:248-51.
41. Ferner RE, Monkman S, Riley J, Cholerton S, Idle JR, Bateman DN. Pharmacokinetics and toxic effects of nifedipine in massive overdose. *Human & experimental toxicology*. 1990;9:309-11.
42. Kleinbloesem CH, van Brummelen P, Faber H, Breimer DD. Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. *J Cardiovasc Pharmacol*. 1987;9:202-8.
43. Hirasawa K, Shen WF, Kelly DT, Roubin G, Tateda K, Shibata J. Effect of food ingestion on nifedipine absorption and haemodynamic response. *European journal of clinical pharmacology*. 1985;28:105-7.
44. Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological

- similarities but fundamental therapeutic differences. *Journal of hypertension*. 2004;22:1641-8.
45. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax*. 2004;59:252-6.
46. Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. *Current cardiology reports*. 2020;22:31.
47. Burki TK. Coronavirus in China. *The Lancet Respiratory Medicine*. 2020;8:238.
48. Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. *Clinical pharmacology and therapeutics*. 2005;78:143-53.
49. Patel N, Polak S, Jamei M, Rostami-Hodjegan A, Turner DB. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2014;57:240-9.
50. Dallmann A, Ince I, Coboecken K, Eissing T, Hempel G. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. *Clinical pharmacokinetics*. 2018;57:749-68.
51. Johnson TN, Boussey K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. *Clinical pharmacokinetics*. 2010;49:189-206.
52. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. *CPT: pharmacometrics & systems pharmacology*. 2012;1:e3-e.
53. Waller DG, Renwick AG, Gruchy BS, George CF. The first pass metabolism of nifedipine in man. *British journal of clinical pharmacology*. 1984;18:951-4.
54. Greenblatt DJ, Harmatz JS. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. *British journal of clinical pharmacology*. 2015;80:342-50.
55. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. *European journal of clinical pharmacology*. 1996;51:189-93.
56. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *Jama*. 2020.